SCHEMBL6472844

SCHEMBL6472844

CCOC(=O)C=Cc1ccc(OC)c(-c2cc3c(cc2OCc2ccc(OCOC)cc2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.47
MAOB P27338 1/20 0.44
MMP1 P03956 5/20 0.42
GSK3B P49841 1/20 0.41
ACHE P22303 4/20 0.41
BCHE P06276 3/20 0.41
CA12 O43570 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
APP P05067 5/20 0.41
MMP2 P08253 2/20 0.40
MMP3 P08254 2/20 0.40
MMP9 P14780 2/20 0.40
MMP12 P39900 2/20 0.40
MMP13 P45452 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6472841 1.00 FDPS (0.47) FDPSMAOBMMP1GSK3BACHE
SCHEMBL6477948 0.93 FDPS (0.50) FDPSMAOBMMP1ACHEBCHE
SCHEMBL6477944 0.93 FDPS (0.50) FDPSMAOBMMP1ACHEBCHE
SCHEMBL6473700 0.93 FDPS (0.45) FDPSMAOBACHEBCHECA12
SCHEMBL6473218 0.93 FDPS (0.45) FDPSMAOBACHEBCHECA12
SCHEMBL6476815 0.91 FDPS (0.53) FDPSMAOBACHEBCHECA12
SCHEMBL6476811 0.91 FDPS (0.53) FDPSMAOBACHEBCHECA12
SCHEMBL6472257 0.91 FDPS (0.51) FDPSMAOBMMP1CA12CA4
SCHEMBL6472256 0.91 FDPS (0.51) FDPSMAOBMMP1CA12CA4
SCHEMBL6472405 0.90 KDM4E (0.47) FDPSMMP1CA12CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R FDPS 3696/4885MAOB 166/4885MMP1 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.